A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
At a glance
- Drugs PF 5089771 (Primary)
- Indications Pain
- Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Pharmacokinetics
- Acronyms FIH SAD study
- Sponsors Pfizer
- 19 Feb 2016 Results of two phase I studies published in the Clinical Pharmacokinetics
- 30 Jan 2012 Actual patient number is 61 according to ClinicalTrials.gov.
- 30 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.